Biotech

All Articles

AstraZeneca articles data on in-house competitors to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared a very early look at the performance of its own in-house antibody-d...

iTeos- GSK's TIGIT superstar reveals meaningful improvement

.After declaring a stage 3 launch based upon positive midstage end results, iTeos and GSK are actual...

More collective FDA can increase rare ailment R&ampD: document

.The FDA must be actually even more available and also joint to release a rise in commendations of u...

Zenas, MBX, Bicara scalp to Nasdaq in hot day for biotech IPOs

.It's an unusually active Friday for biotech IPOs, along with Zenas BioPharma, MBX as well as Bicara...

Atea's COVID antiviral falls short to halt hospitalizations in stage 3

.Atea Pharmaceuticals' antiviral has actually failed an additional COVID-19 test, however the biotec...

Neurocrine's proposal to save schizophrenia possibility falls short

.Neurocrine Biosciences' mental illness program pivot has neglected. The biotech was incapable to im...

Sanofi pays $110M upfront for late-stage radioligand treatment

.Sanofi has actually brought in a late entry to the radioligand gathering, paying one hundred thousa...

F 2G rears $100M for second effort to get brand-new antifungal to market

.After F2G's 1st attempt to acquire a new training class of antifungal to market was actually hinder...

Moderna targets $1.1 B in R&ampD spending slices, falls 5 courses surrounded by productivity pressures

.Moderna has actually pledged to cut R&ampD costs through $1.1 billion by 2027. The choice to retrac...

Sanofi's $80M bet on Pivot dystrophy medication ends in period 3 crash

.Only four months after Sanofi bet $80 million in beforehand money on Fulcrum Therapeutics' losmapim...